Evidence map›Paper›PMID 37962082›Full record

ArticleCancer medicine2023

Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.

Xibin Xiao, Panpan Chen, Yadi Zhong, Xiu Luo, Yao Liu, Ying Lu, Xueli Jin, Wenbin Qian, Weidong Han, Aibin Liang and 1 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Xibin XiaoDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Panpan ChenDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Yadi ZhongDepartment of Bio-Therapeutic, The First Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China.
Xiu LuoDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Yao LiuDepartment of Hematology Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Ying LuDepartment of Hematology, Yinzhou Hospital, Affiliated to College of Medicine, Ningbo University, Ningbo, China.
Xueli JinDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Wenbin QianDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Weidong HanDepartment of Bio-Therapeutic, The First Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China.
Aibin LiangDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Hui LiuDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.ORCID 0000-0003-1452-5062
Second Affiliated Hospital of Zhejiang University · CNChinese PLA General Hospital · CNTongji University · CNChongqing University · CNNingbo University · CN

Funding

Zhejiang Medical Health Science and Technology Project 2021KY166
6 · The paper itself

Abstract

backgroundLittle was known on infection and mortality rates, still less the risk factors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant in B-cell lymphoma patients following CD19 targeted chimeric antigen receptor T cell (CAR-T).

aimsWe performed a retrospective multicenter study and analyzed the details of relapsed/refractory (R/R) B-cell lymphoma patients who received CD19 targeted CAR-T heretofore in five cellular immunotherapy centers in China during the omicron wave. MATERIALS &

methodsOne hundred fifty-four patients were enrolled in this study.

resultsAmong them, 52 patients (33.8%) were uninfected, 74 patients (48.1) had ambulatory mild disease (including nine patients of asymptomatic infection), 22 patients (14.3%) had moderate disease and six patients (3.9%) had severe disease when data collected up. Three patients with severe disease died from COVID-19, the death rate was 1.9% for all enrolled patients, and 2.9% for infected patients. We also found that patients over 60 years old or with diabetes mellitus (DM) tend to develop severe disease (p = 0.0057 and p = 0.0497, respectively). Patients had CAR-T infusion within 6 months also tend to have severe disease (p = 0.0011). In multivariate logistic regression model, CAR-T infusion within 6 months (relative risk (RR) 40.92; confidence interval (CI) 4.03-415.89; p = 0.002) were associated with significantly higher risk of severe disease.

conclusionThrough this study, we conclude that the outcome for B-cell lymphoma patients following CD19 targeted CAR-T therapy when facing omicron infection was improved, but aggressive precautionary measures were particularly crucial for patients with high risk factors.

Indexed as

COVID-19Lymphoma, B-CellReceptors, Chimeric AntigenAdaptor Proteins, Signal TransducingAntigens, CD19HumansImmunotherapy, AdoptiveMiddle AgedRisk FactorsSARS-CoV-2T-LymphocytesAdaptor Proteins, Signal TransducingAntigens, CD19Receptors, Chimeric AntigenB-cell lymphomachimeric antigen receptor T cellomicron variantoutcomesevere acute respiratory syndrome coronavirus 2

Identifiers

PMID37962082
PMCPMC10709723
OpenAlexW4388657323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.